Terms: = Prostate cancer AND XPA, XPAC, 7507, ENSG00000136936, XP1, P23025 AND Treatment
2 results:
1. Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting xpa protein.
Zhang Y; Wei W; Li C; Yan S; Wang S; Xiao S; He C; Li J; Qi Z; Li B; Yang K; Li C
Cell Death Dis; 2022 Dec; 13(12):1034. PubMed ID: 36509750
[TBL] [Abstract] [Full Text] [Related]
2. xpa-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence.
Aufderklamm S; Hennenlotter J; Todenhoefer T; Gakis G; Schilling D; Vogel U; Kuehs U; Dlugosch J; Knapp J; Merseburger A; Gerber V; Ordelheide A; Hevler J; Stenzl A; Schwentner C
World J Urol; 2012 Aug; 30(4):547-52. PubMed ID: 21969130
[TBL] [Abstract] [Full Text] [Related]
